Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | USP2 | O75604 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | RECQL | P46063 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | THRB | P10828 | 4/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetracycline SCHEMBL4932253 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12856676 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12356690 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Epitetracycline SCHEMBL19771301 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL16302914 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL13223984 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL6666071 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL4932271 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL21900130 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT | |
| Tetracycline SCHEMBL12247641 | 1.00 | MEN1 (0.70) | MEN1KMT2ATDP1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1083863-B1 | REDUCTION OF HAIR GROWTH USING INHIBITORS OF MATRIX METALLOPROTEINASES | GILLETTE CO (US) | 2003-09-03 | — | — | EP | claimed |
| US-5962466-A | APPLYING TO SKIN | STYCZYNSKI PETER (US) | 1999-10-05 | — | — | US | claimed |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170260269-A1 | SIGNALLING SYSTEM | Autolus Limited (GB) | 2017-09-14 | — | — | US | disclosed |
| US-4921844-A | 25-AZASTEROLS, B-KETOTHIOLASE INHIBITORS | MERCK & CO., INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4920111-A | SYNERGISTIC | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920109-A | COADMINISTERING A 25-AZASTEROL WITH A NON-STEROIDAL AGENT; NONTOXIC, SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920113-A | TO ERADICATE MYCOTIC INFECTIONS; NONTOXIC, SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4920112-A | SYNERGISTIC 25-AZASTEROL COMPOUND AND SQUALENE EPOXIDASE INHIBITOR | MERCK & CO., INC. (US) | 1990-04-24 | — | — | US | disclosed |
| EP-0339709-A2 | Antifungal compositions and method of controlling mycotic infections | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0339708-A2 | Fungicidal compositions and method | MERCK & CO. INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| EP-0338173-A1 | Ionic dressing for topical administration of drugs to wounds and burns | RICOH KYOSAN INC. (JP) | 1989-10-25 | — | — | EP | disclosed |
| EP-0137212-A2 | Ointment bases and ointments | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | MEN1 4065/4885KMT2A 634/4885TDP1 999/4885 |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | MYC, TET1, TET3 | MEN1 2648/4885KMT2A 1255/4885TDP1 2913/4885 |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | TET1, TET3, MYC | MEN1 1281/4885KMT2A 857/4885TDP1 2522/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | MEN1 3697/4885KMT2A 3257/4885TDP1 1003/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | MEN1 2384/4885KMT2A 1153/4885TDP1 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.